T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive disorder characterized by malignant transformation of immature progenitors primed towards T-cell development. Over the past 15 years, advances in the molecular characterization of T-ALL have uncovered oncogenic key drivers and crucial signaling pathways of this disease, opening new chances for the development of novel therapeutic strategies. Currently, T-ALL patients are still treated with aggressive therapies, consisting of high dose multiagent chemotherapy. To minimize and overcome the unfavorable effects of these regimens, it is critical to identify innovative targets and test selective inhibitors of such targets. Major efforts are being made to develop small molecules against deregulated signaling pathways, which sustain T-ALL cell growth, survival, metabolism, and drug-resistance. This review will focus on recent improvements in the understanding of the signaling pathways involved in the pathogenesis of T-ALL and on the challenging opportunities for T-ALL targeted therapies.

New advances in targeting aberrant signaling pathways in T-cell Acute Lymphoblastic Leukemia / F. Paganelli, A. Lonetti, L. Anselmi, A.M. Martelli, C. Evangelisti, F. Chiarini.. - In: ADVANCES IN BIOLOGICAL REGULATION. - ISSN 2212-4926. - ELETTRONICO. - 74:(2019), pp. 100649.1-100649.15. [10.1016/j.jbior.2019.100649]

New advances in targeting aberrant signaling pathways in T-cell Acute Lymphoblastic Leukemia.

F. Paganelli
Membro del Collaboration Group
;
A. Lonetti
Membro del Collaboration Group
;
A. M. Martelli
Membro del Collaboration Group
;
C. Evangelisti;
2019

Abstract

T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive disorder characterized by malignant transformation of immature progenitors primed towards T-cell development. Over the past 15 years, advances in the molecular characterization of T-ALL have uncovered oncogenic key drivers and crucial signaling pathways of this disease, opening new chances for the development of novel therapeutic strategies. Currently, T-ALL patients are still treated with aggressive therapies, consisting of high dose multiagent chemotherapy. To minimize and overcome the unfavorable effects of these regimens, it is critical to identify innovative targets and test selective inhibitors of such targets. Major efforts are being made to develop small molecules against deregulated signaling pathways, which sustain T-ALL cell growth, survival, metabolism, and drug-resistance. This review will focus on recent improvements in the understanding of the signaling pathways involved in the pathogenesis of T-ALL and on the challenging opportunities for T-ALL targeted therapies.
2019
New advances in targeting aberrant signaling pathways in T-cell Acute Lymphoblastic Leukemia / F. Paganelli, A. Lonetti, L. Anselmi, A.M. Martelli, C. Evangelisti, F. Chiarini.. - In: ADVANCES IN BIOLOGICAL REGULATION. - ISSN 2212-4926. - ELETTRONICO. - 74:(2019), pp. 100649.1-100649.15. [10.1016/j.jbior.2019.100649]
F. Paganelli, A. Lonetti, L. Anselmi, A.M. Martelli, C. Evangelisti, F. Chiarini.
File in questo prodotto:
Eventuali allegati, non sono esposti

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11585/706061
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 2
  • Scopus 3
  • ???jsp.display-item.citation.isi??? ND
social impact